NeuroScientific Biopharmaceuticals Limited develops diagnostic and therapeutic treatments for neurodegenerative diseases through preclinical studies of patented technologies.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.40|
|52 Week High||AU$0.20|
|52 Week Low||AU$0.54|
|1 Month Change||-10.11%|
|3 Month Change||21.21%|
|1 Year Change||29.03%|
|3 Year Change||150.00%|
|5 Year Change||n/a|
|Change since IPO||77.78%|
Recent News & Updates
NeuroScientific Biopharmaceuticals (ASX:NSB) Is In A Good Position To Deliver On Growth Plans
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Companies Like NeuroScientific Biopharmaceuticals (ASX:NSB) Can Afford To Invest In Growth
Just because a business does not make any money, does not mean that the stock will go down. Indeed, NeuroScientific...
Companies Like NeuroScientific Biopharmaceuticals (ASX:NSB) Are In A Position To Invest In Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
|NSB||AU Biotechs||AU Market|
Return vs Industry: NSB exceeded the Australian Biotechs industry which returned 1.7% over the past year.
Return vs Market: NSB exceeded the Australian Market which returned 20.2% over the past year.
Stable Share Price: NSB is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: NSB's weekly volatility (11%) has been stable over the past year.
About the Company
NeuroScientific Biopharmaceuticals Limited develops diagnostic and therapeutic treatments for neurodegenerative diseases through preclinical studies of patented technologies. The company’s lead drug candidates include EmtinB for treatment of neurodegenerative dementia and Alzheimer’s disease, and degenerative conditions of the optic nerve. NeuroScientific Biopharmaceuticals Limited was incorporated in 2002 and is based in Cottesloe, Australia.
NeuroScientific Biopharmaceuticals Fundamentals Summary
|NSB fundamental statistics|
Is NSB overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|NSB income statement (TTM)|
|Cost of Revenue||AU$39.60k|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.022|
|Net Profit Margin||-331.45%|
How did NSB perform over the long term?See historical performance and comparison
Is NeuroScientific Biopharmaceuticals undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate NSB's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate NSB's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: NSB is unprofitable, so we can't compare its PE Ratio to the Global Biotechs industry average.
PE vs Market: NSB is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate NSB's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: NSB is good value based on its PB Ratio (3.9x) compared to the AU Biotechs industry average (4.8x).
How is NeuroScientific Biopharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as NeuroScientific Biopharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has NeuroScientific Biopharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: NSB is currently unprofitable.
Growing Profit Margin: NSB is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: NSB is unprofitable, and losses have increased over the past 5 years at a rate of 41.8% per year.
Accelerating Growth: Unable to compare NSB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NSB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (46.5%).
Return on Equity
High ROE: NSB has a negative Return on Equity (-21.76%), as it is currently unprofitable.
How is NeuroScientific Biopharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: NSB's short term assets (A$14.4M) exceed its short term liabilities (A$223.4K).
Long Term Liabilities: NSB has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: NSB is debt free.
Reducing Debt: NSB had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: NSB has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: NSB has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 44.5% each year
What is NeuroScientific Biopharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate NSB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate NSB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if NSB's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if NSB's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of NSB's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. Matthew Liddelow, BSc, M. Pharm, also known as Matt, serves as Chief Executive Officer, Managing Director & Director of NeuroScientific Biopharmaceuticals Limited. Mr. Liddelow has experience in the co...
CEO Compensation Analysis
Compensation vs Market: Matt's total compensation ($USD325.63K) is about average for companies of similar size in the Australian market ($USD302.06K).
Compensation vs Earnings: Matt's compensation has increased whilst the company is unprofitable.
Experienced Management: NSB's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.
Experienced Board: NSB's board of directors are not considered experienced ( 1 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 82.6%.
NeuroScientific Biopharmaceuticals Limited's employee growth, exchange listings and data sources
- Name: NeuroScientific Biopharmaceuticals Limited
- Ticker: NSB
- Exchange: ASX
- Founded: 2002
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$57.389m
- Shares outstanding: 143.47m
- Website: https://www.neuroscientific.com
- NeuroScientific Biopharmaceuticals Limited
- 85 Forrest Street
- Suite 5
- Western Australia
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/20 15:35|
|End of Day Share Price||2021/10/20 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.